Position in NVCT
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$66,918
+$3,249 QoQ
Shares Held
8,657
+2.7% QoQ
Ownership
0.033%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
9 quarters on record
Voting authority
Sole 33%
Shared 0%
None 67%
Common Shares in NVCT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026RHUMBLINE ADVISERS holds $1,237,848,251 across 287 Biotechnology names. NVCT ranks #234 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
423,140 | $188,948,935 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
157,781 | $121,907,911 | |
| 3 | INCY |
Incyte Corp
|
693,665 | $65,287,749 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
195,277 | $64,611,300 | |
| 5 | INSM |
INSMED Inc
|
272,615 | $44,578,004 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
164,542 | $31,106,665 | |
| 7 | EXEL |
Exelixis, Inc.
|
723,931 | $31,049,400 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
1,113,266 | $30,837,468 |
All Filings in NVCT
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $66,918 | 8,657 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $63,669 | 8,433 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $68,206 | 11,330 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $94,704 | 12,678 | Shares | Sole | 2025-08-12 | |
| 2024-06-30 | $11,843 | 1,871 | Shares | Sole | 2024-08-01 | |
| 2024-03-31 | $61,516 | 7,502 | Shares | Sole | 2024-05-09 | |
| 2023-12-31 | $60,656 | 7,273 | Shares | Sole | 2024-02-08 | |
| 2023-09-30 | $93,748 | 7,273 | Shares | Sole | 2023-11-09 | |
| 2023-06-30 | $108,244 | 6,778 | Shares | Sole | 2023-08-08 | |
| No filing history on record for this holder in this stock. | ||||||